Point-of-Care Testing: An Introduction

OBJECTIVE: To review available literature and provide perspective on point-of-care testing, focusing on the impact it has on treatment outcomes in patient care, the impact it has on the costs of patient care, and the role it has in the delivery of pharmaceutical care. DATA SOURCES: Information was retrieved from MEDLINE English literature searches using PubMed (1965–August 2003) and included search terms of point-of-care testing, near patient testing, pharmaceutical care, pharmacists, outcomes, and economics. Additionally, references from retrieved articles were reviewed to identify literature not detected by literature searches. STUDY SELECTION AND DATA EXTRACTION: Comparative studies, demonstration project reports, and systematic reviews were selected. Other related resources, such as government documents, relevant legislation, and government regulations, were included. Emphasis was placed on comparative studies and demonstration project reports. In the absence of these data, other resources were included. DATA SYNTHESIS: Point-of-care testing devices and technology are increasingly used in the delivery of care and therapeutic decision making. No studies have evaluated the impact of point-of-care testing, by itself, on patient care and outcomes. All studies have incorporated point-of-care testing with changes in the way patient care is delivered and have shown significant improvements when this approach is taken. The cost of point-of-care testing is greater than traditional laboratory testing, but the increased cost may be offset by improvements in the management of patient care, improvements in patient outcomes, and decreased utilization of the healthcare system. Point-of-care testing has been used successfully by pharmacists in disease management programs. Various government regulations and legislation impact the use of point-of-care testing. CONCLUSIONS: Limited data indicate that point-of-care testing, when combined with changes in healthcare delivery systems, may improve patient outcomes and decrease the overall cost of health care. Pharmacists have used point-of-care testing in programs designed to improve patient care but must carefully consider regulations and laws that govern the use of these devices. There is a great need for additional investigation into the use of point-of-care testing in patient care.

[1]  W. Maughan,et al.  Clinical outcomes of point-of-care testing in the interventional radiology and invasive cardiology setting. , 2000, Clinical chemistry.

[2]  D. Nathan,et al.  Utilization and cost analysis of bedside capillary glucose testing in a large teaching hospital: implications for managing point of care testing. , 1994, The American journal of medicine.

[3]  J. Boldt,et al.  Point-of-care (POC) measurement of coagulation after cardiac surgery , 1998, Intensive Care Medicine.

[4]  G. Gravlee,et al.  Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation. , 1990, The Journal of thoracic and cardiovascular surgery.

[5]  B. Luce,et al.  The Economic and Clinical Efficiency of Point-of-Care Testing for Critically Ill Patients: A Decision-Analysis Model , 1998, American journal of medical quality : the official journal of the American College of Medical Quality.

[6]  D. Jobes,et al.  Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. , 1995, The Journal of thoracic and cardiovascular surgery.

[7]  D. Christensen,et al.  The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. , 2003, Journal of the American Pharmaceutical Association.

[8]  C. Hepler,et al.  Opportunities and responsibilities in pharmaceutical care. , 1990, American journal of hospital pharmacy.

[9]  J. Nosanchuk,et al.  Cost analysis of point-of-care laboratory testing in a community hospital. , 1995, American journal of clinical pathology.

[10]  G J Kost,et al.  Preventing medical errors in point-of-care testing: security, validation, safeguards, and connectivity.. , 2001, Archives of pathology & laboratory medicine.

[11]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[12]  P. St-Louis Status of point-of-care testing: promise, realities, and possibilities. , 2000, Clinical biochemistry.

[13]  R. Grieve,et al.  Near patient testing in diabetes clinics: appraising the costs and outcomes. , 1999, Health technology assessment.

[14]  L. Goodnough,et al.  Monitoring of hemostasis in cardiac surgical patients: impact of point-of-care testing on blood loss and transfusion outcomes. , 1997, Clinical chemistry.

[15]  G. Raskob,et al.  Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. , 1997, Archives of internal medicine.

[16]  L. Kohn,et al.  To Err Is Human : Building a Safer Health System , 2007 .

[17]  G. Kost Guidelines for point-of-care testing. Improving patient outcomes. , 1995, American journal of clinical pathology.

[18]  J W Winkelman,et al.  The fiscal consequences of central vs distributed testing of glucose. , 1994, Clinical chemistry.

[19]  D. Greenblatt,et al.  Influence of serum digoxin concentration measurements on frequency of digitoxicity , 1974, Clinical pharmacology and therapeutics.

[20]  W. Rosenthal Establishing a pharmacy-based laboratory service. , 2000, Journal of the American Pharmaceutical Association.

[21]  M. Rupp,et al.  Developing and marketing a community pharmacy-based asthma management program. , 1997, Journal of the American Pharmaceutical Association.

[22]  R H Christenson,et al.  Cardiac markers: point of care testing. , 1999, Clinica chimica acta; international journal of clinical chemistry.

[23]  R. Becker,et al.  Bedside coagulation monitoring in heparin-treated patients with active thromboembolic disease: a coronary care unit experience. , 1994, American heart journal.

[24]  J. Mckenney,et al.  Pharmaceutical care services and results in project ImPACT: hyperlipidemia. , 2000, Journal of the American Pharmaceutical Association.